keyword
MENU ▼
Read by QxMD icon Read
search

american society of clinical oncology

keyword
https://www.readbyqxmd.com/read/28644913/supplement-2-for-the-2004-update-of-the-aapm-task-group-no-43-report-joint-recommendations-by-the-aapm-and-gec-estro
#1
Mark J Rivard, Facundo Ballester, Wayne M Butler, Larry A DeWerd, Geoffrey S Ibbott, Ali S Meigooni, Christopher S Melhus, Michael G Mitch, Ravinder Nath, Panagiotis Papagiannis
Since publication of the 2004 update to the American Association of Physicists in Medicine (AAPM) Task Group No. 43 Report (TG-43U1) and its 2007 supplement (TG-43U1S1), several new low-energy photon-emitting brachytherapy sources have become available. Many of these sources have satisfied the AAPM prerequisites for routine clinical purposes and are posted on the Brachytherapy Seed Registry managed jointly by the AAPM and the Imaging and Radiation Oncology Core Houston Quality Assurance Center (IROC Houston)...
June 23, 2017: Medical Physics
https://www.readbyqxmd.com/read/28618241/use-of-adjuvant-bisphosphonates-and-other-bone-modifying-agents-in-breast-cancer-a-cancer-care-ontario-and-american-society-of-clinical-oncology-clinical-practice-guideline
#2
Sukhbinder Dhesy-Thind, Glenn G Fletcher, Phillip S Blanchette, Mark J Clemons, Melissa S Dillmon, Elizabeth S Frank, Sonal Gandhi, Rasna Gupta, Mihaela Mates, Beverly Moy, Ted Vandenberg, Catherine H Van Poznak
Purpose To make recommendations regarding the use of bisphosphonates and other bone-modifying agents as adjuvant therapy for patients with breast cancer. Methods Cancer Care Ontario and ASCO convened a Working Group and Expert Panel to develop evidence-based recommendations informed by a systematic review of the literature. Results Adjuvant bisphosphonates were found to reduce bone recurrence and improve survival in postmenopausal patients with nonmetastatic breast cancer. In this guideline, postmenopausal includes patients with natural menopause or that induced by ovarian suppression or ablation...
June 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28596092/stereotactic-body-radiation-therapy-for-early-stage-non-small-cell-lung-cancer-executive-summary-of-an-astro-evidence-based-guideline
#3
Gregory M M Videtic, Jessica Donington, Meredith Giuliani, John Heinzerling, Tomer Z Karas, Chris R Kelsey, Brian E Lally, Karen Latzka, Simon S Lo, Drew Moghanaki, Benjamin Movsas, Andreas Rimner, Michael Roach, George Rodrigues, Shervin M Shirvani, Charles B Simone, Robert Timmerman, Megan E Daly
PURPOSE: This guideline presents evidence-based recommendations for stereotactic body radiation therapy (SBRT) in challenging clinical scenarios in early-stage non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: The American Society for Radiation Oncology convened a task force to perform a systematic literature review on 4 key questions addressing: (1) application of SBRT to operable patients; (2) appropriate use of SBRT in tumors that are centrally located, large, multifocal, or unbiopsied; (3) individual tailoring of SBRT in "high-risk" clinical scenarios; and (4) SBRT as salvage therapy after recurrence...
June 5, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28596016/multi-disciplinary-summit-on-genetics-services-for-women-with-gynecologic-cancers-a-society-of-gynecologic-oncology-white-paper
#4
Leslie M Randall, Bhavana Pothuri, Elizabeth M Swisher, John P Diaz, Adam Buchanan, Catherine T Witkop, C Bethan Powell, Ellen Blair Smith, Mark E Robson, Jeff Boyd, Robert L Coleman, Karen Lu
OBJECTIVE: To assess current practice, advise minimum standards, and identify educational gaps relevant to genetic screening, counseling, and testing of women affected by gynecologic cancers. METHODS: The Society of Gynecologic Oncology (SGO) organized a multidisciplinary summit that included representatives from the American College of Obstetricians and Gynecologists (ACOG), the American Society Clinical Oncology (ASCO), the National Society of Genetic Counselors (NSGC), and patient advocacy groups, BrightPink and Facing our Risk of Cancer Empowered (FORCE)...
June 7, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28592400/dual-checkpoint-blockade-takes-aim-at-relapsed-mesothelioma
#5
(no author information available yet)
In the largest clinical trial to date of immune checkpoint inhibitors for mesothelioma, patients treated with nivolumab-either alone or in combination with ipilimumab-posted impressive response rates and survival outcomes, according to data presented at the 2017 American Society of Clinical Oncology Annual Meeting. However, the combination, although more effective, was also more toxic.
June 7, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28592399/dacomitinib-beats-gefitinib-for-egfr-nsclc
#6
(no author information available yet)
The irreversible EGFR inhibitor dacomitinib reduced the chance of lung cancer progression compared with an older, first-generation EGFR inhibitor, gefitinib, in a phase III trial. As reported at the 2017 American Society of Clinical Oncology Annual Meeting, the experimental drug also increased toxicity, which could limit its use, especially with a safer, more effective third-generation EGFR inhibitor not far behind in the development pipeline.
June 7, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28588061/dual-her2-blockade-helps-prevent-breast-cancer-return
#7
(no author information available yet)
Adding pertuzumab to an adjuvant regimen of trastuzumab for women with early-stage HER2(+) breast cancer reduces the risk of disease recurrence, especially among those with node-positive and hormone receptor-negative disease. Results from the phase III APHINITY trial, which could help pertuzumab earn full approval for this indication, were presented at the 2017 American Society of Clinical Oncology Annual Meeting.
June 6, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28583794/delivery-of-meaningful-cancer-care-a-retrospective-cohort-study-assessing-cost-and-benefit-with-the-asco-and-esmo-frameworks
#8
Joseph C Del Paggio, Richard Sullivan, Deborah Schrag, Wilma M Hopman, Biju Azariah, C S Pramesh, Ian F Tannock, Christopher M Booth
BACKGROUND: The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) have developed frameworks that quantify survival gains in light of toxicity and quality of life to assess the benefits of cancer therapies. We applied these frameworks to a cohort of contemporary randomised controlled trials to explore agreement between the two approaches and to assess the relation between treatment benefit and cost. METHODS: We identified all randomised controlled trials of systemic therapies in non-small-cell lung cancer, breast cancer, colorectal cancer, and pancreatic cancer published between Jan 1, 2011, and Dec 31, 2015, and assessed their abstracts and methods...
June 2, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28582371/clinical-presentation-and-anatomical-location-of-orbital-plasmacytomas
#9
Bradley A Thuro, Oded Sagiv, Roman Shinder, J Matthew Debnam, Omar Ozgur, John D Ng, Daniel Rootman, Sheeba K Thomas, Bita Esmaeli
PURPOSE: To evaluate the clinical and anatomical location of orbital plasmacytomas and assess local control following therapy. METHODS: The American Society of Ophthalmic Plastic and Reconstructive Surgery Oncology Database was queried to identify patients diagnosed with orbital plasmacytoma. These patients' records were reviewed for demographic characteristics, clinical and radiologic findings, treatments, and outcomes. RESULTS: Thirty patients from 4 institutions (24 from MD Anderson Cancer Center, 3 from SUNY Downstate Medical Center, 2 from University of California, Los Angeles, and 1 from Oregon Health and Science University) were identified...
June 2, 2017: Ophthalmic Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/28577940/trends-practice-patterns-and-underuse-of-surgery-in-the-treatment-of-early-stage-small-cell-lung-cancer
#10
E Wakeam, T K Varghese, N B Leighl, M Giuliani, S R G Finlayson, G E Darling
BACKGROUND: Practice guidelines from the National Comprehensive Cancer Network and the American Society of Clinical Oncology recommend pathologic mediastinal staging and surgical resection for patients with clinically node-negative T1/T2 small cell lung cancer (SCLC), but the extent to which surgery is used is unknown. We sought to assess trends and practice patterns in the use of surgery for SCLC. METHODS: T1 or T2N0M0 SCLC cases were identified in the National Cancer Database (NCDB), 2004-2013...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28576857/braf-mutations-as-predictive-biomarker-for-response-to-anti-egfr-monoclonal-antibodies
#11
Emilie M J van Brummelen, Anthonius de Boer, Jos H Beijnen, Jan H M Schellens
Recently, the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) recommended that patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer could be treated with anti-EGFR monoclonal antibodies (mAbs) cetuximab and panitumumab only in absence of Rat-Sarcoma (RAS) mutations. In addition to the previously established biomarker Kirsten rat sarcoma viral oncogene homolog (KRAS) exon 2, cumulative evidence also shows that patients whose tumors harbor KRAS exons 3 or 4 and neuroblastoma rat-sarcoma viral oncogene homolog (NRAS) exons 2, 3, and 4 mutations are found unlikely to benefit from anti-EGFR treatment...
June 2, 2017: Oncologist
https://www.readbyqxmd.com/read/28575861/diagnostic-accuracy-of-pcr-for-detecting-alk-gene-rearrangement-in-nsclc-patients-a-systematic-review-and-meta-analysis
#12
Xia Zhang, Jian-Guo Zhou, Hua-Lian Wu, Hu Ma, Zhi-Xia Jiang
BACKGROUND: Anaplastic lymphoma kinase (ALK) gene fusion has been reported in 3~5% non-small cell lung carcinoma (NSCLC) patients, and polymerase chain reaction (PCR) is commonly used to detecting the gene status, but the diagnostic capacity of it is still controversial. A systematic review and meta-analysis was conducted to clarify the diagnostic accuracy of PCR for detecting ALK gene rearrangement in NSCLC patients. RESULTS: 18 articles were enrolled, which included 21 studies, involving 2800 samples from NSCLC patients...
May 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28574778/do-the-american-society-of-clinical-oncology-value-framework-and-the-european-society-of-medical-oncology-magnitude-of-clinical-benefit-scale-measure-the-same-construct-of-clinical-benefit
#13
Sierra Cheng, Erica J McDonald, Matthew C Cheung, Vanessa S Arciero, Mahin Qureshi, Di Jiang, Doreen Ezeife, Mona Sabharwal, Alexandra Chambers, Dolly Han, Natasha Leighl, Kelley-Anne Sabarre, Kelvin K W Chan
Purpose Whether the ASCO Value Framework and the European Society for Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale (MCBS) measure similar constructs of clinical benefit is unclear. It is also unclear how they relate to quality-adjusted life-years (QALYs) and funding recommendations in the United Kingdom and Canada. Methods Randomized clinical trials of oncology drug approvals by the US Food and Drug Administration, European Medicines Agency, and Health Canada between 2006 and August 2015 were identified and scored using the ASCO version 1 (v1) framework, ASCO version 2 (v2) framework, and ESMO-MCBS by at least two independent reviewers...
June 2, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28569658/long-term-care-safe-drug-handling-of-oral-chemotherapy
#14
Tali M Johnson
Many oral chemotherapy agents have been approved over the last 15 years and are displacing or augmenting parenteral chemotherapy. As 8,000 Baby Boomers turn 65 years of age every day, more elders will migrate to long-term care and assisted living facilities, and consultant pharmacists may need to manage chemotherapy for the first time. Though many therapeutic classes of oral drugs are hazardous, the majority of oral chemotherapy agents are hazardous by virtue of their mechanisms of action. Previous hazardous drug-handling recommendations from the Occupational Safety and Health Administration, the National Institute of Occupational Safety and Health, the American Society of Health-System Pharmacists, the American Society of Clinical Oncology, the Hematology/Oncology Pharmacy Association, and the Oncology Nursing Society have matured into new standards from the United States Pharmacopeial Convention (USP), Chapter <800>, "Hazardous Drugs-Handling in Health Care Settings...
February 1, 2017: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
https://www.readbyqxmd.com/read/28556024/cancer-of-the-esophagus-and-esophagogastric-junction-major-changes-in-the-american-joint-committee-on-cancer-eighth-edition-cancer-staging-manual
#15
Thomas W Rice, Donna M Gress, Deepa T Patil, Wayne L Hofstetter, David P Kelsen, Eugene H Blackstone
Answer questions and earn CME/CNE New to the eighth edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual for epithelial cancers of the esophagus and esophagogastric junction are separate, temporally related cancer classifications: 1) before treatment decision (clinical); 2) after esophagectomy alone (pathologic); and 3) after preresection therapy followed by esophagectomy (postneoadjuvant pathologic). The addition of clinical and postneoadjuvant pathologic stage groupings was driven by a lack of correspondence of survival, and thus prognosis, between both clinical and postneoadjuvant pathologic cancer categories (facts about the cancer) and pathologic categories...
May 26, 2017: CA: a Cancer Journal for Clinicians
https://www.readbyqxmd.com/read/28554108/indirect-comparison-between-pembrolizumab-and-nivolumab-for-the-treatment-of-non-small-cell-lung-cancer-a-meta-analysis-of-randomized-clinical-trials
#16
Tzu-Rong Peng, Fang-Pei Tsai, Ta-Wei Wu
OBJECTIVE: The purpose of this study is to evaluate the efficacy and adverse effects of nivolumab and pembrolizumab for the treatment of advanced non-small-cell lung cancer (NSCLC) by meta-analysis. MATERIALS AND METHODS: This meta-analysis of randomized controlled trials (RCTs) was performed after searching PubMed, EMBASE, and American Society of Clinical Oncology meeting abstracts, clinicaltrial gov, and Cochrane library databases. Two reviewers independently assessed the quality of the trials...
May 26, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/28542918/multisite-external-validation-of-a-risk-prediction-model-for-the-diagnosis-of-blood-stream-infections-in-febrile-pediatric-oncology-patients-without-severe-neutropenia
#17
Adam J Esbenshade, Zhiguo Zhao, Catherine Aftandilian, Raya Saab, Rachel L Wattier, Melissa Beauchemin, Tamara P Miller, Jennifer J Wilkes, Michael J Kelly, Alison Fernbach, Michael Jeng, Cindy L Schwartz, Christopher C Dvorak, Yu Shyr, Karl G M Moons, Maria-Luisa Sulis, Debra L Friedman
BACKGROUND: Pediatric oncology patients are at an increased risk of invasive bacterial infection due to immunosuppression. The risk of such infection in the absence of severe neutropenia (absolute neutrophil count ≥ 500/μL) is not well established and a validated prediction model for blood stream infection (BSI) risk offers clinical usefulness. METHODS: A 6-site retrospective external validation was conducted using a previously published risk prediction model for BSI in febrile pediatric oncology patients without severe neutropenia: the Esbenshade/Vanderbilt (EsVan) model...
May 23, 2017: Cancer
https://www.readbyqxmd.com/read/28541789/primary-prevention-of-cervical-cancer-american-society-of-clinical-oncology-resource-stratified-guideline-summary
#18
Silvia de Sanjosé, Sarah Temin, Suzanne Garland, Linda O'Neal Eckert, Silvina Arrossi
No abstract text is available yet for this article.
May 25, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28535106/value-tools-in-managed-care-decision-making-current-hurdles-and-future-opportunities
#19
Jeremy Schafer, Dominic Galante, Jason Shafrin
BACKGROUND: Organizations such as the National Comprehensive Cancer Network, American Society of Clinical Oncology, Institute for Clinical and Economic Review, and Memorial Sloan Kettering have created distinct tools to help different stakeholders assess the value of oncology treatments. However, the oncology value tools were not necessarily created for payers, and it is unclear whether payers are using these tools as part of their drug management process. OBJECTIVE: To understand what value tools payers are using in oncology management and what benefits and shortcomings the tools may have from the payer perspective...
June 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28535105/the-importance-of-economic-perspective-and-quantitative-approaches-in-oncology-value-frameworks-of-drug-selection-and-shared-decision-making
#20
A Reginald Waldeck, Marc F Botteman, Richard E White, Ben A van Hout
The debate around value in oncology drug selection has been prominent in recent years, and several professional bodies have furthered this debate by advocating for so-called value frameworks. Herein, we provide a viewpoint on these value frameworks, emphasizing the need to consider 4 key aspects: (1) the economic underpinnings of value; (2) the importance of the perspective adopted in the valuation; (3) the importance of the difference between absolute and relative measures of risk and measuring patient preferences; and (4) the recognition of multiple quality-of-life (QoL) domains, and the aggregation and valuation of those domains, through utilities within a multicriteria decision analysis, may allow prioritization of QoL above the tallying of safety events, particularly in a value framework focusing on the individual patient...
June 2017: Journal of Managed Care & Specialty Pharmacy
keyword
keyword
77718
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"